Hemophilia A Clinical Trials in Iowa City, Iowa

4 studies are recruiting for hemophilia a in Iowa City, Iowa right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

    WP44714 is a Phase I/II, open-label, non-randomized, global, multicenter trial consisting of two parts: * Part 1 is a multiple-ascending dose (MAD) study in adult and adolescent male participants with severe or moderate hemophilia A with or without factor VIII (FVIII) inhibitors. * Part 2 is a mult…

    Stage
    Phase 1
    Ages
    2 to 59
    Site
    University of Iowa Hospitals and Clnics Dept of Pediatrics, Iowa City, Iowa
    Locations
    14 in total
    Run by
    Hoffmann-La Roche

    See if you can join NCT05987449 on ClinicalTrials.gov

  2. A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A

    The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of NXT007 prophylaxis compared with Factor VIII (FVIII) prophylaxis in participants with severe or moderate congenital hemophilia A without FVIII inhibitors. The study will include people aged ≥12 y…

    Stage
    Phase 3
    Ages
    12 and older
    Site
    University of Iowa Hospitals and Clinics, Iowa City, Iowa
    Locations
    27 in total
    Run by
    Hoffmann-La Roche

    See if you can join NCT07416526 on ClinicalTrials.gov

  3. A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A

    The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of NXT007 prophylaxis compared with emicizumab prophylaxis in people age 12 years and older with severe or moderate congenital hemophilia A without factor VIII (FVIII) inhibitors or with hemophilia…

    Stage
    Phase 3
    Ages
    12 and older
    Site
    University Of Iowa Hospitals And Clinics, Iowa City, Iowa
    Locations
    42 in total
    Run by
    Hoffmann-La Roche

    See if you can join NCT07416604 on ClinicalTrials.gov

  4. Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

    Study B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Termination" from the Phase 3 Study B7841005 and from the Phase 3 Study B7841008. Study B7841005: approxima…

    Stage
    Phase 3
    Ages
    1 to 74
    Site
    University of Iowa, Iowa City, Iowa
    Locations
    75 in total
    Run by
    Pfizer

    See if you can join NCT05145127 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.